In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually disease progression or maybe the contributors are not able to tolerate the study drugs. then boost H3K27Ac at this location. Chromatin hyperacetylation could increase the https://keikoy211lvf3.qodsblog.com/profile